Skip to Content

Candelaria Gomez-Manzano, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Tenure, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Tenure, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX
Faculty, Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  • Cancer stem cells
  • Brain tumors
  • Tie2-multicompartmental role
  • E2F pathway

The research in my laboratory is focused inunderstanding the cause of resistance of gliomas to therapies, and hasan important translational component. Because the current tenet onbrain tumor stem cells as cells responsible for the recurrence ofgliomas after surgery and for the resistance of these tumors tochemotherapy and radiotherapy, the development of cancer stemcell-based tumor models will be of great utility for uncovering themolecular mechanism responsible for the resistance of malignant gliomasto conventional therapies.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1002
Houston, TX 77030-4009
Room Number: BSRB, Rm S5.8316A
Phone: 713-834-6260
Fax: 713-834-6230

Education & Training

Degree-Granting Education

1988 University Central of Barcelona, Barcelona, Spain, MD, Medicine

Postgraduate Training

9/1994-10/1997 Research Fellowship, Experimental Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, WK Alfred Yung, M.D.
3/1989-12/1992 Clinical Residency, Neurology, University Autonomous of Barcelona, Barcelona, Spain


Academic Appointments

Assistant Professor, tenure-track, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2008-8/2013
Assistant Professor, tenure-track, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2013
Assistant Professor, non-tenure track, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2002-8/2007
Instructor, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/1999-8/2002
Research Associate, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/1997-10/1999

Administrative Appointments/Responsibilities

Director, Training in Brain Tumor Research, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2011-present
Liason for the Department of Neuro-Oncology, Women Faculty Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010-present

Other Appointments/Responsibilities

Member, Search Committee Neurosurgery Research Faculty Recruitment, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2013
Member, Best Presentation Selection Committee, Graduate School of Biomedical Sciences, Cancer Biology Program, Houston, TX, 2011
Admission Process, MD/PhD Program, University of Texas, Houston, TX, 2010-present
Admission Process, Graduate School of Biomedical Sciences, University of Texas, Houston, TX, 2009-present

Institutional Committee Activities

Faculty Member, Postdoctoral Advisory Committee, 9/2013-present
Member Committee, Basic Sciences, Institutional Research Grants, 9/2011-present
Member, Advisory Committee. 2009 Knudson Award to the Best PhD Dissertation, 2009

Honors and Awards

2014 Nomination- Regents' Outstanding Teaching Awards 2014, The University of Texas System
2014 Nomination- Robert M. Chamberlain Distinguished Mentor Award, MD Anderson Cancer Center
2012 Waun Ki Hong Award for Excellence Team Science (Delta-24 Program), UT MD Anderson Cancer Center
2009 Nomination for Waun Ki Hong Award for Excellence Team Science (Delta-24 Program), University of Texas M.D. Anderson Cancer Center
2003 Outstanding Educator, The University of Texas M. D. Anderson Cancer Center
1995 Travel grant, American Association for Cancer Research

Professional Memberships

American Academy of Neurology (AAN), Saint Paul, MN
Associate Member, 2000-present
American Association for Cancer Research (AACR), Philadelphia, PA
Active Member, 2004-present
American Association for the Advancement of Science (AAAS), Washington, DC
Member, 2011-present
Society for Neuro-Oncology (SNO), Houston, TX
Member, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gabrusiewicz K, Hossain MB, Cortes-Santiago N, Fan X, Kaminska B, Marini FC, Fueyo J, Gomez-Manzano C. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia 17(4):374-84, 4/2015. PMID: 25925380.
2. Klein SR, Piya S, Lu Z, Xia Y, Alonso MM, White EJ, Wei J, Gomez-Manzano C, Jiang H, Fueyo J. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene. e-Pub 1/2015. PMID: 25619840.
3. Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS, Toledo G, Fueyo J, Gomez-Manzano C, Torre W, Lecanda F, Patiño-García A, Alonso MM. The Oncolytic Adenovirus Delta24-RGD in Combination with Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. J Bone Miner Res 29(10):2287-96, 10/2014. e-Pub 4/2014. PMID: 24737304.
4. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 5(8):2208-20, 4/2014. PMCID: PMC4039157.
5. Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 5/2014. PMCID: PMC4020829.
6. Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108(10):2005-12, 5/2013. e-Pub 4/2013. PMCID: PMC3670480.
7. Jiang H, White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity. J Virol 85(10):4720-9, 5/2011. e-Pub 3/2011. PMCID: PMC3126198.
8. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF121/rGel on Vascular Endothelial Cells Resulting in Inhibition of Angiogenesis is Mediated via VEGFR-2. BMC Cancer 11:358, 2011. e-Pub 8/2011. PMCID: PMC3176242.
9. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, de Munain AL, Sampron N, Aramburu A, Tejada-Solis S, Vicente C, Odero MD, Bandres E, Garcia-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6(11):e26740, 2011. e-Pub 11/2011. PMCID: PMC3206066.
10. Piya S, White EJ, Klein SR, Jiang H, McDonnell TJ, Gomez-Manzano C*, Fueyo J*. *, [co-corresponding authors]. The E1B19K oncoprotein complexes with Beclin 1 to regulate autophagy in adenovirus-infected cells. PLoS One 6(12):e29467, 2011. e-Pub 12/2011. PMCID: PMC3248451.
11. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. Oncotarget 1(8):700-9, 12/2010. PMCID: PMC3100177.
12. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 10/2010. e-Pub 8/2010. PMID: 20807803.
13. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):289-297, 4/2010. e-Pub 10/2009. PMID: 19876078.
14. Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24). e-Pub 5/2009. PMID: 19421150.
15. Piao Y, Jiang H, Alemany R, Krasnykn V, Marini FC, Xu J, Alonso MM, Conrad C, Aldape KD, Gomez-Manzano C, Fueyo J.. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3). e-Pub 10/2008. PMID: 18927600.
16. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C*, Fueyo J* [equal contribution]. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-93, 3/2008. e-Pub 2/2008. PMID: 18253154.
17. Lee OH, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C.. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene 27(9):1310-1314, 2/2008. e-Pub 8/2007. PMID: 17704802.
18. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad C, Aldape KD, deGroot JF, Bekele BN, Yung WK.. VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 2008. e-Pub 8/2008. PMID: 18708344.
19. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J.. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 67(24):11499-504, 12/2007. PMID: 18089777.
20. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J.. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4, 9/2007. e-Pub 9/2007. PMID: 17848677.
21. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J.. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 67(17):8255-63, 9/2007. PMID: 17804740.
22. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J.. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 8/2007. e-Pub 6/2007. PMID: 17557108.
23. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J [co-corresponding author]. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4009, 5/2007. PMID: 17483310.
24. Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 12/2006. PMID: 17065226.
25. Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4:915-26, 12/2006. PMID: 17189382.
26. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8:419-28, 5/2006. PMCID: PMC1592446.
27. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 1/2006. PMID: 16428500.
28. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 11/2005. PMID: 16264179.
29. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 8/2005. PMID: 16207474.
30. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-94, 3/2005. PMID: 15650766.
31. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. PMID: 15720816.
32. Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 11/2004. PMID: 15332115.
33. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 3/2004. PMID: 15014451.
34. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 6/2003. PMID: 12714585.
35. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 5/2003. PMID: 12734316.
36. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. PMID: 12509854.
37. Mitlianga PG, Gomez-Manzano C, Kyritsis AP, Fueyo J. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol 21(5):1015-20, 11/2002. PMID: 12370749.
38. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19(2):359-65, 8/2001. PMID: 11445852.
39. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9):1252-7, 5/2001. PMID: 11336478.
40. Mitlianga PG, Kyritsis AP, Gomez-Manzano C, Lemoine MG, Hu M, Liu TJ, Yung WK, Fueyo J. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol 18(2):343-7, 2/2001. PMID: 11172602.
41. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1):2-12, 1/2000. PMID: 10644974.
42. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59(4):895-900, 2/1999. PMID: 10029081.
43. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4(6):685-90, 6/1998. PMID: 9623977.
44. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50(5):1307-15, 5/1998. PMID: 9595979.
45. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 3/1998. PMID: 9472109.
46. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 10/1997. PMID: 9366522.
47. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 7/1997. PMID: 9230885.
48. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-9, 10/1996. PMID: 8895506.
49. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 2/1996. PMID: 8630997.
50. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1/1996. PMID: 8552379.
51. EAFT group (includes Gomez-Manzano C). Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation Trial. Neurology 46(1):159-65, 1/1996. PMID: 8559367.
52. Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 12/1995. PMID: 8808318.
53. Singer DE, Hylek EM, and EAFT group (includes Gomez-Manzano C). Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333(22):1504, 11/1995. PMID: 7477157.
54. EAFT group (includes Gomez-Manzano). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342(8882):1255-62, 11/1993. PMID: 7901582.

Invited Articles

1. Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 13. e-Pub 4/2015. PMID: 25863716.
2. Klionsky DJ, Abdalla FC, Abeliovich H, et al. (included Gomez-Manzano C). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 4/2012. PMCID: PMC3404883.
3. Hossain MB,Cortes-Santiago N, Liu D, Martin V, Gomez-Manzano C. TEK (TEK tyrosine kinase, endothelial). Atlas Genet Cytogenet Oncol Haematol 16(9):669-673, 4/2012.
4. Balvers R, Jiang H, Piya S, Gomez-Manzano C, Fueyo J. Adenovirus, Autophagy, and Lysis: Ecstasies and Agonies. Future Virology 6(10):1161-1164, 10/2011.
5. Fueyo J, Gomez-Manzano C, Yung WK. Advances in Translational Research in Neuro-Oncology. Arch Neurol 68(3):303-8, 3/2011. e-Pub 11/2010. PMCID: PMC3109723.
6. White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J, Jiang H. Autophagy regulation in cancer development and therapy. Am J Cancer Res 1(3):362-372, 2011. e-Pub 1/2010. PMID: 21969237.
7. Jiang H, Martin V, Alonso M, Gomez-Manzano C, Fueyo J. Rb-E2F1: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 11/2010. e-Pub 11/2010. PMID: 20935482.
8. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther 12(5):530-7, 10/2010. PMID: 20886384.
9. Jiang H, Gomez-Manzano C, Lang F, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 9(5):422-7, 10/2009. PMID: 19860656.
10. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. Methods in Enzymology 453(Autophagy in Disease and Clinical Applications):273-86, 1/2009. PMID: 19216911.
11. Liu D, Martin V, Gomez-Manzano C. TEK (TEK tyrosine kinase, endothelial). Atlas Genet Cytogenet Oncol Haematol 13(12):975-977, 1/2009. e-Pub 1/2009.
12. Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 15(4):353-64, 2009. PMID: 19199963.
13. Martin V, Liu D, Fueyo J, Gomez-Manzano C.. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23(6):773-80, 6/2008. PMID: 18366015.
14. Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C.. E2F1 in gliomas: A paradigm of oncogene addiction. Cancer Lett 263(2):157-63, 5/2008. e-Pub 3/2008. PMID: 18334281.
15. Gomez-Manzano C, Alonso M, Jiang H, Fueyo J.. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2/2008. PMID: 18756625.
16. Jiang H, White EJ, Gomez-Manzano C, Fueyo J.. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy 4(1):118-20, 2008. e-Pub 11/2007. PMID: 18032923.
17. Alonso MM, Fueyo J, Yung WKA, Gomez-Manzano C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 5(9):930-5, 5/2006. e-Pub 5/2006. PMID: 16628012.
18. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6:697-708, 5/2006. PMID: 16759161.
19. Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 63(3):418-26, 8/2004. PMID: 15304571.
20. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenovirus for malignant glioma therapy. Frontiers in Bioscience 8:D577-88, 2003.


1. Conrad CA, Fueyo J, Gomez-Manzano C. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16(8):1025-6, 8/2014. e-Pub 7/2014. PMCID: PMC4096184.

Book Chapters

1. Balvers RK, Gomez-Manzano C, Jiang H, Piya S, Klein SR, Lamfers MLM, Dirven CMF, Fueyo J. Advances in Oncolytic Virotherapy for Brain Tumors. In: Gene Therapy of Cancer, 3rd. Ed(s) Ec Lattime, SL Gerson. Elsevier: San Diego, CA, USA, 137-151, 2014.
2. Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene Therapy. In: Handb Clin Neurol. 104, 3rd. Ed(s) W Grisold, R Soffietti. Elsevier: Edinburgh, UK, 331-8, 2012. ISBN: 22230451.
3. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. In: Methods Mol Biol. 797. Ed(s) D Kirn, S Thorne, T-C Liu. Humana Press, 111-25, 2012. PMCID: PMC3397800.
4. Alonso M, Fueyo J, Gomez-Manzano C. Malignant Gliomas: Role of E2F1 Transcription Factor. In: Methods of Cancer Diagnosis, Therapy, and Prognosis. 1. Ed(s) MA Hayat. Springer, 89-97, 2011. ISBN: 978-94-007-0343-8.

Letters to the Editor

1. Fueyo J, Gomez-Manzano C, Pascual J, Pou A. Paraneoplastic syndromes. Neurology 43(1):236, 1993. PMID: 8380908.

Last updated: 8/26/2015